A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms TAPER
- Sponsors Novartis; Novartis Pharmaceuticals
- 14 Apr 2019 Planned End Date changed from 16 Nov 2020 to 13 May 2022.
- 14 Apr 2019 Planned primary completion date changed from 13 Nov 2020 to 13 May 2022.
- 15 Nov 2018 Planned End Date changed from 30 Aug 2020 to 16 Nov 2020.